Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

EIP Pharma initiates phase II study of neflamapimod in cognitive dysfunction associated with DLB

July 15, 2019

Interim phase Ib data on ACI-24 to treat Alzheimer's disease-like symptoms in Down syndrome

July 12, 2019

Novartis and Amgen discontinue pivotal studies of CNP-520 for Alzheimer's disease

July 12, 2019

Roche discloses new gamma-secretase inhibitors

July 12, 2019

Lundbeck describes new PDE1 inhibitors

July 12, 2019

NDFIP1 may be a novel target for prevention and treatment of Parkinson's disease

July 12, 2019

New insights into old Fountain of Youth

July 11, 2019

Results presented from the international pivotal phase III PLEO-CMT study of PXT-3003

July 10, 2019

EIP Pharma initiates phase II study of neflamapimod for the treatment of cognitive deficits in HD

July 10, 2019

Disordered protein domains stay disordered at work

July 10, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
Roche reports new TREM2 agonists
BioWorld Science
F. Hoffmann-la Roche Ltd. and Hoffmann-La Roche Inc. have identified new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for...
Genescience presents STAT6 degrader for atopic dermatitis
BioWorld Science
Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation....
Sangamo presents primate data for prion suppressor ST-506
BioWorld Science
Sangamo Therapeutics Inc. discussed gene regulation approaches for neurodegenerative diseases when presenting findings on their clinical candidate ST-506 for the...